Clinical Trial Update: Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) [Phase 2]

View source ↗

Summary

Phase 2 efficacy/safety study of ACTIQ for opioid-tolerant children and adolescents with breakthrough pain due to cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breakthrough Pain
• Cancer

Drugs mentioned

• Actiq (fentanyl)

Snippet

Sponsor: Cephalon | Conditions: Cancer, Breakthrough Pain | Phase 2 | Status: COMPLETED